Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bac13f787ec38618dd1ff0b65d9d58856> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bac13f787ec38618dd1ff0b65d9d58856 NCIT_P378 "NCI" @default.
- Bac13f787ec38618dd1ff0b65d9d58856 type Axiom @default.
- Bac13f787ec38618dd1ff0b65d9d58856 annotatedProperty IAO_0000115 @default.
- Bac13f787ec38618dd1ff0b65d9d58856 annotatedSource NCIT_C116876 @default.
- Bac13f787ec38618dd1ff0b65d9d58856 annotatedTarget "An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion." @default.